Skip to main content

Table 4 Results of multiple regression analysis of DRDs

From: Factors associated with positive and negative recommendations for cancer and non-cancer drugs for rare diseases in Canada

Variables in the model

OR (95%CI)

Presence of RCTs (ref.: no)

2.9 (0.7; 11.8)

Safety issues (ref: yes)

4.0 (1.2; 13.6)

Improvements in clinical outcomes (ref: yes)

20.6 (2.2; 189.7)

Improvements in patient reported outcomes (ref: yes)

12.1 (1.3; 110.5)

Consistency between population in trial and indications (ref: no)

3.5 (0.9; 12.7)

  1. 95%CI 95% confidence interval, DRDs drugs for rare diseases, OR odds ratio, RCT randomized controlled trial, ref. reference
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172